ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CONR Conor Medsystems

0.00
0.00 (0.00%)
Last Updated: -
Delayed by 15 minutes
Share Name Share Symbol Market Type
Conor Medsystems NASDAQ:CONR NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

Boston Scientific Sues Conor Medsystems Ireland Ltd.

04/05/2006 5:50pm

PR Newswire (US)


Conor Medsystems (NASDAQ:CONR)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more Conor Medsystems Charts.
NATICK, Mass., May 4 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE:BSX) announced today that it has filed a lawsuit in Ireland against Conor Medsystems Ireland Ltd. (NASDAQ:CONR), alleging that the Conor CoStar(TM) Paclitaxel-Eluting Coronary Stent System infringes a balloon catheter patent owned by Boston Scientific. Boston Scientific is asking for damages and an injunction to prohibit Conor from making, offering, putting on the market or stocking the product in Ireland. The asserted patent is the Irish counterpart of the European patent that Boston Scientific has successfully asserted against Johnson & Johnson in the Netherlands. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/. This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission. CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation DATASOURCE: Boston Scientific Corporation CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or Paul Donovan, Media Relations, +1-508-650-8541, both of Boston Scientific Corporation Web site: http://www.bostonscientific.com/

Copyright

1 Year Conor Medsystems Chart

1 Year Conor Medsystems Chart

1 Month Conor Medsystems Chart

1 Month Conor Medsystems Chart